艾司奥美拉唑方案治疗慢性胃炎患者反流的临床研究  

Esomeprazole regimen for reflux symptoms in patients with chronic gastritis

作　　者：徐成龙 程海俐 张彩凤 吴国斌 XU Cheng-long;CHENG Hai-li;ZHANG Cai-feng;WU Guo-bin(Division 2,Department of Gastroenterology,Cangzhou People's Hospital Headquarters,061000 Cangzhou,Hebei,China;Department of Gastroenterology,Shijiazhuang People's Hospital,061100 Shijiazhuang,Hebei,China)

机构地区：[1]沧州市人民医院本部消化内科二区,河北沧州061000 [2]石家庄市人民医院消化内科,河北石家庄061100

出　　处：《临床消化病杂志》2024年第4期265-269,共5页Chinese Journal of Clinical Gastroenterology

基　　金：河北省2023年度医学科学研究课题计划(No:20231603);2021年沧州市科技计划自筹经费项目(No:213106029)。

摘　　要：[目的]对比艾司奥美拉唑2周与8周方案对胃镜检查阴性的非糜烂性反流病和慢性胃炎患者的疗效,以期为临床诊治提供参考。[方法]将反流病和慢性胃炎患者均给予艾司奥美拉唑20 mg、1次/d,采用8周或2周方案。主要终点是维持/按需治疗期第24周的症状控制率,次要终点是症状缓解率、成功率(定义为在初始治疗和维持治疗24周后症状缓解的患者)、首次复发时间和满意率。[结果]8周方案(8周组)对比2周方案(2周组)的症状控制率差异有统计学意义(94.9%比87.3%,P=0.0473)。在次级终点中,8周组在最初的艾司奥美拉唑治疗后症状缓解效果略好于2周组(88.3%比83.4%,P=0.2513),2组整个研究的成功率比较P=0.0258(83.8%比72.8%)。与2周组相比,8周组的复发风险降低了46%(HR=0.543;95%CI:0.388~0.761)。2组之间的安全性相当,2种方案耐受性均很好。[结论]非糜烂性反流病患者使用8周方案较慢性胃炎患者2周方案反流症状的控制略好一些,安全性相似。[Objective]To compare the efficacy of esomeprazole regimen in patients with endoscopic diagnosed non-erosive reflux disease and chronic gastritis with,so as to provide reference for clinical diagnosis and treatment.[Methods]Patients with reflux disease and chronic gastritis were given esomeprazole 20 mg once daily for an 8-week or 2-week regimen.The primary endpoint was symptom control rate at week 24 of the maintenance/on demand treatment period,and secondary endpoints were symptom remission rate,success rate(defined as patients whose symptoms resolved after 24 weeks of initial treatment and maintenance treatment),time to first recurrence,and satisfaction rate.[Results]There was significant difference in symptom control rate between the 8-week regimen and the 2-week regimen(94.9%vs 87.3%,P=0.0473).Among secondary endpoints,the 8 wk group had slightly better symptom relief after initial esomeprazole treatment(88.3%vs 83.4%,P=0.2513)and success rates across the study(83.8%vs 72.8%,P=0.0258).The risk of recurrence was 46%lower in the 8-week regimen compared to the 2-week regimen(HR=0.543;95%CI:0.388-0.761).Safety was comparable between the two groups,and both regimens were well tolerated.[Conclusions]In patients diagnosed with chronic gastritis,an 8-week esomeprazole regimen compared with a 2-week esomeprazole regimen resulted in slightly better control of reflux symptoms and similar safety.

关 键 词：非糜烂性反流病 艾司奥美拉唑 慢性胃炎方案 症状控制率 

分 类 号：R573.9[医药卫生—消化系统]